Celldex Announces Initial Positive Results from Phase 1

–Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium– HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—mast cell depletion via stem cell factor … Read more

Aspocomp has carried out a Directed Share Issue and agreed

Aspocomp Group Plc., Inside information, Stock Exchange Release, October 30, 2025, at 9.50 p.m. (UCT+2) Aspocomp has carried out a Directed Share Issue and agreed on new long-term financing arrangement to secure growth Aspocomp Group Plc’s Board of Directors has today on October 30, 2025, carried out a directed share issue (the “Directed Share Issue”), … Read more

Aspocomp on toteuttanut suunnatun osakeannin sekä sopinut

Aspocomp Group Plc., Sisäpiiritieto, Pörssitiedote, 30.10 2025, klo 21.50  Aspocomp on toteuttanut suunnatun osakeannin sekä sopinut uusista pitkäaikaisista rahoitusjärjestelyistä kasvun turvaamiseksi Aspocomp Group Oyj:n hallitus on tänään, 30.10.2025, toteuttanut suunnatun osakeannin (”Suunnattu osakeanti”) tietyille yhtiön nykyisille osakkeenomistajille sekä rajoitetulle määrälle suomalaisia ammattimaisia sijoittajia poiketen osakkeenomistajien etuoikeudesta merkitä osakkeita, varmistaen osakeannin onnistuneen toteutumisen. Suunnatun osakeannin tarkoituksena … Read more

How Are Annual Flu Vaccines Made?

How Are Annual Flu Vaccines Made? Immunologist Zachary Rubin explains how the World Health Organization decides which strains of influenza end up in annual flu vaccines. By Zachary Rubin edited by Kelso Harper This video is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi … Read more

2025 third-quarter results Strong performance driving Net

Paris (France), October 30, 2025 2025 third-quarter resultsStrong performance driving Net Cash Flow generation Segment revenue of $313m in Q3 2025, up +27% year-on-year, with all business lines contributing positively Segment adjusted EBITDAs of $167m in Q3 2025, up a massive +70% year-on-year, representing a 53% margin (vs 40% in Q3 2024), supported by strong … Read more

Mise à disposition du troisième

MISE À DISPOSITION DU TROISIЀME AMENDEMENT AU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025  Information réglementée Paris, le 30 octobre 2025 Société Générale informe le public que le troisième amendement au Document d’enregistrement universel 2025, déposé le 12 mars 2025 sous le numéro D-25-0088, a été déposé auprès de l’Autorité des Marchés Financiers (AMF) le 30 octobre 2025 … Read more

Availability of the third amendment to

AVAILABILITY OF THE THIRD AMENDMENT TO 2025 UNIVERSAL REGISTRATION DOCUMENT Regulated Information Paris, 30 October 2025 Societe Generale hereby informs the public that the third amendment to the 2025 Universal Registration Document filed on 12 March 2025 under number D-25-0088, has been filed with the French Financial Markets Authority (AMF) on 30 October 2025 under … Read more